Sentences with phrase «with reports to that effect»

Dear Author noted on this post at The Digital Reader with reports to that effect, and links to further reading on the matter.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

As I've been reporting this week, the Trump administration's threats to cut off insurer payments that help low - income Americans with their deductibles and out - of - pocket medical costs has already had a real - world effect on markets.

These latest reports and in particular the Productivity commission are nonsence to say that it will have a marked effect on the overseas On - Line sales is absolute rubbish.My daughter is in retail in Sydney the problem with overseas On - Line they pay no tax eg GST super, the list goes on we forget WA metro has say 1.8 m people Sydney has 6m Bondi Junction which is probiably the largest shopping centre in Sydney is shut at 6 o, clock most nights The gov keeps going on about the east and what they do Wayne Spencer and co are mouth peaces for the large retailers.My main concern is the On - Lne which is destroying Australias retail ecnomy if it fails being our largest employer the country will be in huge trouble economicly.I have spelt this out in detail in an Email to Bill Shorten if you would like a copy

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

One group looked at the effect of sleep loss on productivity at four American companies and found employees who weren't sleeping well or enough to be roughly twice as likely to report difficulties with time management, decision - making and motivation.

«Even if they did, or if Mr. Trump were able to pass a major infrastructure spending package, they would prove inflationary, causing the Federal Reserve to respond with a faster pace of monetary tightening that would offset the positive effect on growth,» the Economist Intelligence Unit report says.

In a well - publicized report titled the «Red Sneaker Effect,» doctoral candidate Silvia Bellezza explored the idea that high - status thinkers and business people tend to break free of the rules — eating with their mouths open, eschewing blazers for T - shirts and forgetting to shave for weeks on end.

Actual results may differ materially from those indicated by these forward - looking statements as a result of various important factors including, but not limited to, the effects of any unexpected difficulty in closing our financial books for the quarter and other factors that are discussed in the Company's Annual Report on Form 10 - K, quarterly reports on Form 10 - Q, and other documents periodically filed with the SEC.

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward - looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payers to cover Cologuard and adequately reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 10 - Q.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

(c) The following table sets forth all transactions with respect to Shares effected during the past sixty (60) days by any of the Reporting Persons.

Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions, including with respect to the Merger; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and / or guaranty fund assessments; uncertainties surrounding participation in government - sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; our ability to obtain shareholder or regulatory approvals required for the Merger or the requirement to accept conditions that could reduce the anticipated benefits of the Merger as a condition to obtaining regulatory approvals; a longer time than anticipated to consummate the proposed Merger; problems regarding the successful integration of the businesses of Express Scripts and Cigna; unexpected costs regarding the proposed Merger; diversion of management's attention from ongoing business operations and opportunities during the pendency of the Merger; potential litigation associated with the proposed Merger; the ability to retain key personnel; the availability of financing, including relating to the proposed Merger; effects on the businesses as a result of uncertainty surrounding the proposed Merger; as well as more specific risks and uncertainties discussed in our most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.cigna.com as well as on Express Scripts» most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.express-scripts.com.

Thus, while concluding that the NGP is likely to result in significant adverse environmental effects with respect to caribou and grizzly bears, the JRP recommended that these «can be justified in the circumstances, as set out in Chapter 2» (see NGP Report, Volume II, Chapter 8, Environmental Assessment).

From a strictly legal perspective, the relevant question is not whether there is a sufficient connection to any particular existing or proposed oil sands development or other production activity, and certainly not whether such projects or activities were included in the Terms of Reference (ToR), but rather simply whether the GHGs associated with the production of bitumen that will be transported by the NGP are an «environmental effect» of that project (see NGP Report, Volume II, Appendix 4, Terms of Reference, which defines «environmental effect» very broadly to mean «any change that the project may cause in the environment.»

Actual results may vary materially from those expressed or implied by forward - looking statements based on a number of factors, including, without limitation: (1) risks related to the consummation of the Merger, including the risks that (a) the Merger may not be consummated within the anticipated time period, or at all, (b) the parties may fail to obtain shareholder approval of the Merger Agreement, (c) the parties may fail to secure the termination or expiration of any waiting period applicable under the HSR Act, (d) other conditions to the consummation of the Merger under the Merger Agreement may not be satisfied, (e) all or part of Arby's financing may not become available, and (f) the significant limitations on remedies contained in the Merger Agreement may limit or entirely prevent BWW from specifically enforcing Arby's obligations under the Merger Agreement or recovering damages for any breach by Arby's; (2) the effects that any termination of the Merger Agreement may have on BWW or its business, including the risks that (a) BWW's stock price may decline significantly if the Merger is not completed, (b) the Merger Agreement may be terminated in circumstances requiring BWW to pay Arby's a termination fee of $ 74 million, or (c) the circumstances of the termination, including the possible imposition of a 12 - month tail period during which the termination fee could be payable upon certain subsequent transactions, may have a chilling effect on alternatives to the Merger; (3) the effects that the announcement or pendency of the Merger may have on BWW and its business, including the risks that as a result (a) BWW's business, operating results or stock price may suffer, (b) BWW's current plans and operations may be disrupted, (c) BWW's ability to retain or recruit key employees may be adversely affected, (d) BWW's business relationships (including, customers, franchisees and suppliers) may be adversely affected, or (e) BWW's management's or employees» attention may be diverted from other important matters; (4) the effect of limitations that the Merger Agreement places on BWW's ability to operate its business, return capital to shareholders or engage in alternative transactions; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings, including any such proceedings related to the Merger and instituted against BWW and others; (6) the risk that the Merger and related transactions may involve unexpected costs, liabilities or delays; (7) other economic, business, competitive, legal, regulatory, and / or tax factors; and (8) other factors described under the heading «Risk Factors» in Part I, Item 1A of BWW's Annual Report on Form 10 - K for the fiscal year ended December 25, 2016, as updated or supplemented by subsequent reports that BWW has filed or files with the SEC.

They also report lower intention to leave the firm for another job, but consistent with the idea that the context matters, the favorable effects appear to depend on the presence of other supportive workplace policies.

First reported as a partnership that would find the state - owned bank collaborating directly with the Ethereum Foundation, the non-profit for which Buterin serves as council, the VEB has confirmed it will be retracting public statements to that effect.

These risks and uncertainties include: fluctuations in U.S. and international economies and currencies, our ability to preserve, grow and leverage our brands, potential negative effects of material breaches of our information technology systems if any were to occur, costs associated with, and the successful execution of, the company's initiatives and plans, the acceptance of the company's products by our customers, the impact of competition, coffee, dairy and other raw material prices and availability, the effect of legal proceedings, and other risks detailed in the company filings with the Securities and Exchange Commission, including the «Risk Factors» section of Starbucks Annual Report on Form 10 - K for the fiscal year ended September 28, 2014.

Income reporting would instead show that short - term corrections have little effect on long - term outcomes, giving participants the potential encouragement to stay the course with their financial plan.

They work with corporations to increase the availability of animal product alternatives and have developed a «restaurant report card» to score the top 100 chain restaurants according to their plant - based options.22 In general, we think that corporate outreach is a relatively effective animal advocacy intervention, though we are less certain of the effects of promoting plant - based options in restaurants than we are of the effects of working with corporations to implement welfare reforms.

We are particularly concerned by reports that this order went into effect with little to no consultation with the Departments of State, Defense, Justice, and Homeland Security... Ultimately, we fear this executive order will become a self - inflicted wound in the fight against terrorism.

This effect is most common if you have failed to properly mix the psyllium husk with water or have undergone bowel surgery, reports MedlinePlus.

Therefore it is with regret that I report that I feel the changes in the new standard regarding shade criteria have negative effects and, due to lack of transparency, I can no longer recommend Rainforest Alliance certified coffee to consumers specifically seeking «shade grown» coffee.

Next up is struggling Crystal Palace and with the game being played at the Emirates stadium on new years day and looking at Palace's league position and recent form you might think it is another three points in the bag, except for the fact that they have a new manager in the shape of Sam Allardyce and according to a Sky Sports report the Palace defender Martin Kelly reckons that the Big Sam effect is already making itself felt at Selhurst Park.

Stindl has only eighteen months remaining on his current contract, with the report claiming a release clause of just # 2.2 m comes into effect in the summer transfer window, which would no doubt make him a potential bargain if he did make the move to Anfield.

Perhaps he's talked candidly with Popovich and the players; there has been no reporting to that effect, though, and Leonard has been radio silent in public, which in fairness is not particularly odd for him.

However, Giroud also linked up with the German to great effect this weekend and he spoke about how well their understanding has grown, as reported by the Daily Mail.

That is the line QPR boss Harry Redknapp is spinning to potential new recruits, with quotes to that effect widely reported in the...

While all but three states now have laws requiring immediate removal from play of athletes with concussion signs or symptoms and prohibit same - day return to play for those with suspected concussion, some are concerned that such laws may have the perverse effect of making the under - reporting problem even worse, fearing that an athlete is going to be even less likely to self - report experiencing concussion symptoms and more likely to hide symptoms from teammates, game officials and sideline personnel if they know that a suspected concussion may sideline them for the rest of the game.

Chemicals with estrogenic activity «have been reported to have potential adverse health effects in mammals, including humans, especially in fetal and infant states,» says Dr. George Bittner, a professor of neurobiology at the University of Texas at Austin who has served on many National Institutes of Health panels.

As well as bonding with the baby when sharing the breastfeeding, lesbian parents report enjoying the effects of the relaxation hormones released when lactating (resulting in lower stress levels in the parent and baby), the flexibility of having two nursing parents when one needs to absent herself occasionally or when returning to work, and the health benefits of breastfeeding such as lower rates of breast cancer, ovarian cancer and Type II diabetes (8), (9).

However, lessons were learned from these early programmes and in 2004, the Texas Fragile Families initiative reported an increase in child support orders / paternity establishment among its participants (with a «dose» effect — the longer the young father was involved in the programme, the more likely he was to establish paternity / pay child support); and employment rates up from 50 % at the start of the programme to almost 70 % at six months and 80 % at one year (Romo et al, 2004).

Although none of the groups reported on drug side effects, while Guo who tested only breastfed infants reported on significant decrease in infant crying, and decrease in depressive symptoms at one month and at two months respectively, Sung who tested both formula fed and breastfed infants reported on increase crying in the probiotic treated infants (particularly in the formula fed infants) compared to placebo with no effect on maternal depressive symptoms.

FDA: «FDA Drug Safety Communication: Reports of a rare, but serious and potentially fatal adverse effect with the use of OTC benzocaine gels and liquids applied to the gums or mouth.»

Of note, our point estimate for premature death exceeds the annual number of U.S. deaths from cervical cancer (3,909), asthma (3,361), or influenza (3,055).45 If a randomized control trial were to demonstrate similar effects to those reported in the observational literature, the «number needed to treat» with optimal breastfeeding to prevent a case of maternal hypertension would be 35, to prevent a maternal MI would be 135, and to prevent a case of breast cancer would be 385.

Twenty - nine percent of children 2 to 3 years of age have a television in their bedroom, and 30 % of parents have reported that watching a television program enabled their children to fall asleep.3 Although parents perceive a televised program to be a calming sleep aid, some programs actually increase bedtime resistance, delay the onset of sleep, cause anxiety about falling asleep, and shorten sleep duration.41 Specifically, in children younger than 3 years, television viewing is associated with irregular sleep schedules.42 Poor sleep habits have adverse effects on mood, behavior, and learning.

A series of randomized control trials of a nurse home visitation program show a range of positive effects on maternal health, including decreases in prenatal cigarette smoking, fewer hypertensive disorders in pregnancy, and fewer closely spaced subsequent pregnancies., A randomized control study of another program that works with a particularly high - risk population found that participant mothers showed significantly lower depressive symptoms than those in the control group and were less likely to report feeling stressed a year after participation.

In two studies, mothers reported more negative emotional behaviour in their preschool - aged children who formerly had colic, although there were no differences in all other reported behaviour problems when compared to infants who did not have colic.20, 21 Finally, several studies have also examined mental development in infants with colic and likewise have demonstrated no effect of colic.15, 16,20,22 In one study, although differences on the Bayley MDI were revealed at six months, both groups were within the normal range, and no differences were found at 12 months of age.23

There are now 400 reports of adverse side effects — including 10 deaths — associated with these products, according to the FDA.

Morbidity and mortality The reported risk of food allergy at 12 months of age was statistically significantly reduced among exclusively breastfed infants relative to mixed breastfed infants by 81 % (RR 0.19, 95 % CI [0.08 to 0.48], p = 0.00036; 1 study / 135 infants); however, when double - challenged with food in the same study, the effect size was reduced and became non-significant (RR 0.77, 95 % CI [0.25 to 2.41], p = 0.66).

If your child does have a serious side effect that is associated with taking an antibiotic, you can report it to the FDA through their MedWatch online voluntary reporting form.

FDA Drug Safety Communication: Reports of a rare, but serious and potentially fatal adverse effect with the use of over-the-counter (OTC) benzocaine gels and liquids applied to the gums or mouth.

Tough documents the devastating effects of adverse childhood experiences on children's ability to cope with stress, and he reports on recent educational programs to help students develop «non-cognitive» skills - grit, optimism, curiosity, zest, social intelligence, gratitude, and self - control — that are essential to success in life.

With new reports of a drinkable sunscreen and summer's arrival, it's time to brush up on sun safety information and ideas to keep you and your family safe from the sun's harmful and damaging effects.

However, the report qualified this by saying that «in terms of national resource use, the economic effects of a ban on hunting would be unlikely to be substantial», with the effects most likely to have dissipated within a decade, but that in the short term «the individual and local effects would be more serious».

If the contract sums were in excess of the thresholds approved by the PPA, it begs the question why these issues were not pointed out in the report of the tender evaluation panel, why the Deputy Chairpersons as member so the Review Panel did not point this out and why the Deputy Chairperson CS would approve the payments to Clicotech and Cads Contracts (same contracts, issued through same process) and ensure that payments on the contracts were effected without the approval of the Chairperson and with no notice to her.

More than two of every five Americans reside in counties with unhealthy levels of smog and air pollution, thanks largely to the effect of global warming, health researchers report.

• Partnership with the Electoral Commission to study individual electoral registration effects, culminating in a joint report.

In most cases, the surcharges were initially met with hostility, but the positive effects have been hard to deny: Immediately following the initiation of zone charging, London saw congestion reduced by a quarter, average speeds increase by 30 percent, and carbon dioxide emissions decrease by 20 percent, per the Fix NYC report.